Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy

We report the first case of 68-year-old Japanese woman with metastatic HER2-positive extramammary Paget’s disease that showed the validity of trastuzumab monotherapy. We administered trastuzumab at a loading dose of 8 mg/kg i.v., followed by a 6 mg/kg maintenance dose every three weeks according to...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Wakabayashi, Y. Togawa, K. Yoneyama, K. Suehiro, N. Kambe, H. Matsue
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Case Reports in Dermatological Medicine
Online Access:http://dx.doi.org/10.1155/2012/401362
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849308628548321280
author S. Wakabayashi
Y. Togawa
K. Yoneyama
K. Suehiro
N. Kambe
H. Matsue
author_facet S. Wakabayashi
Y. Togawa
K. Yoneyama
K. Suehiro
N. Kambe
H. Matsue
author_sort S. Wakabayashi
collection DOAJ
description We report the first case of 68-year-old Japanese woman with metastatic HER2-positive extramammary Paget’s disease that showed the validity of trastuzumab monotherapy. We administered trastuzumab at a loading dose of 8 mg/kg i.v., followed by a 6 mg/kg maintenance dose every three weeks according to a protocol for HER2-positive metastatic breast cancers and a near-complete response was achieved after the tenth infusion. The patient experienced a moderate headache and flushing during the first infusion, but had no advanced effects during subsequent infusions with ibuprofen and d-chlorpheniramine maleate. Given the dramatic response, the patient has had 17 infusions of trastuzumab with no disease progression. Thus, trastuzumab has few side effects and is well tolerated for elderly patients. It may become a new choice of the adjubant therapy of this disease.
format Article
id doaj-art-0dab494c18774af8b3e5f607f136ca50
institution Kabale University
issn 2090-6463
2090-6471
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Case Reports in Dermatological Medicine
spelling doaj-art-0dab494c18774af8b3e5f607f136ca502025-08-20T03:54:24ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712012-01-01201210.1155/2012/401362401362Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab MonotherapyS. Wakabayashi0Y. Togawa1K. Yoneyama2K. Suehiro3N. Kambe4H. Matsue5Department of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Dermatology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanWe report the first case of 68-year-old Japanese woman with metastatic HER2-positive extramammary Paget’s disease that showed the validity of trastuzumab monotherapy. We administered trastuzumab at a loading dose of 8 mg/kg i.v., followed by a 6 mg/kg maintenance dose every three weeks according to a protocol for HER2-positive metastatic breast cancers and a near-complete response was achieved after the tenth infusion. The patient experienced a moderate headache and flushing during the first infusion, but had no advanced effects during subsequent infusions with ibuprofen and d-chlorpheniramine maleate. Given the dramatic response, the patient has had 17 infusions of trastuzumab with no disease progression. Thus, trastuzumab has few side effects and is well tolerated for elderly patients. It may become a new choice of the adjubant therapy of this disease.http://dx.doi.org/10.1155/2012/401362
spellingShingle S. Wakabayashi
Y. Togawa
K. Yoneyama
K. Suehiro
N. Kambe
H. Matsue
Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
Case Reports in Dermatological Medicine
title Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
title_full Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
title_fullStr Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
title_full_unstemmed Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
title_short Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
title_sort dramatic clinical response of relapsed metastatic extramammary paget s disease to trastuzumab monotherapy
url http://dx.doi.org/10.1155/2012/401362
work_keys_str_mv AT swakabayashi dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy
AT ytogawa dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy
AT kyoneyama dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy
AT ksuehiro dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy
AT nkambe dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy
AT hmatsue dramaticclinicalresponseofrelapsedmetastaticextramammarypagetsdiseasetotrastuzumabmonotherapy